Bangkok Genomics Innovation Public Company Limited(TH:BKGI)
฿2.100.00 (0.00%)
TH:BKGI
Bangkok Genomics Innovation Public Company Limited financials statements
฿2.10
At close:0.00 (0.00%)
Bangkok Genomics Innovation Public Company Limited (BKGI) Ratios
Bangkok Genomics Innovation Public Company Limited Ratios
TH:BKGI's free cash flow for Q2 2026 was ฿22.74M. For the 2026 fiscal year, TH:BKGI's free cash flow was decreased by ฿-11.90M and operating cash flow was ฿34.64M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.58 | 11.27 | 5.96 | 8.79 | 4.66 |
| Quick Ratio | 4.29 | 10.79 | 5.68 | 7.94 | 4.09 |
| Cash Ratio | 1.75 | 8.54 | 3.54 | 6.20 | 1.72 |
| Solvency Ratio | 0.45 | 0.99 | 0.84 | 1.69 | 2.97 |
| Operating Cash Flow Ratio | -0.70 | -0.08 | 2.02 | 3.39 | 1.89 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | ฿ 431.65M | ฿ 446.48M | ฿ 154.88M | ฿ 157.49M | ฿ 98.48M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.04 | 0.08 | 0.11 | 0.06 |
| Debt-to-Equity Ratio | 0.04 | 0.04 | 0.10 | 0.13 | 0.07 |
| Debt-to-Capital Ratio | 0.04 | 0.04 | 0.09 | 0.11 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.27 | 1.13 | 1.24 | 1.21 | 1.26 |
| Debt Service Coverage Ratio | 42.60 | 51.01 | 30.32 | 84.43 | 160.66 |
| Interest Coverage Ratio | 29.40 | 39.63 | 20.02 | 59.97 | 148.13 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.04 | 0.04 | 0.04 | 0.05 | 0.07 |
| Net Debt to EBITDA | -3.13 | -5.22 | -2.06 | -1.24 | -0.35 |
| Profitability Margins | |||||
| Gross Profit Margin | 39.54% | 41.49% | 47.31% | 50.49% | 43.51% |
| EBIT Margin | 11.17% | 15.52% | 13.69% | 26.16% | 28.12% |
| EBITDA Margin | 16.85% | 20.78% | 20.19% | 30.93% | 30.35% |
| Operating Profit Margin | 11.17% | 15.95% | 13.38% | 21.14% | 27.92% |
| Pretax Profit Margin | 12.61% | 15.11% | 13.02% | 25.81% | 27.93% |
| Net Profit Margin | 11.95% | 14.86% | 13.10% | 24.65% | 27.86% |
| Continuous Operations Profit Margin | 11.94% | 14.86% | 13.10% | 24.65% | 27.86% |
| Net Income Per EBT | 94.78% | 98.33% | 100.62% | 95.49% | 99.75% |
| EBT Per EBIT | 112.86% | 94.75% | 97.28% | 122.06% | 100.02% |
| Return on Assets (ROA) | 6.46% | 8.26% | 10.97% | 24.99% | 56.28% |
| Return on Equity (ROE) | 8.23% | 9.34% | 13.63% | 30.33% | 70.79% |
| Return on Capital Employed (ROCE) | 7.37% | 9.58% | 12.75% | 23.29% | 66.89% |
| Return on Invested Capital (ROIC) | 6.93% | 9.35% | 12.55% | 21.91% | 65.71% |
| Return on Tangible Assets | 6.68% | 8.26% | 11.01% | 25.10% | 56.37% |
| Earnings Yield | 6.05% | 4.02% | 3.29% | 7.68% | 40.51% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.28 | 4.20 | 8.36 | 7.84 | 5.50 |
| Payables Turnover | 2.79 | 8.31 | 11.06 | 60.68 | 11.57 |
| Inventory Turnover | 6.36 | 8.94 | 12.86 | 7.44 | 12.79 |
| Fixed Asset Turnover | 4.95 | 4.28 | 3.49 | 3.71 | 7.79 |
| Asset Turnover | 0.54 | 0.56 | 0.84 | 1.01 | 2.02 |
| Working Capital Turnover Ratio | 0.82 | 1.05 | 1.35 | 2.07 | 6.79 |
| Cash Conversion Cycle | 86.38 | 83.73 | 39.06 | 89.57 | 63.38 |
| Days of Sales Outstanding | 160.03 | 86.82 | 43.68 | 46.54 | 66.41 |
| Days of Inventory Outstanding | 57.40 | 40.82 | 28.38 | 49.04 | 28.53 |
| Days of Payables Outstanding | 131.05 | 43.91 | 33.00 | 6.02 | 31.56 |
| Operating Cycle | 217.43 | 127.64 | 72.06 | 95.58 | 94.94 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.15 | -0.01 | 0.12 | 0.14 | 0.35 |
| Free Cash Flow Per Share | -0.21 | -0.04 | 0.11 | 0.09 | 0.26 |
| Dividend Paid and CapEx Coverage Ratio | -1.37 | -0.18 | 1.47 | 0.42 | 4.13 |
| Capital Expenditure Coverage Ratio | -2.43 | -0.18 | 14.91 | 2.88 | 4.13 |
| Operating Cash Flow Coverage Ratio | -4.11 | -0.15 | 3.03 | 2.57 | 5.23 |
| Operating Cash Flow to Sales Ratio | -0.23 | -0.01 | 0.29 | 0.27 | 0.15 |
| Free Cash Flow Yield | -16.59% | -1.88% | 6.83% | 5.42% | 16.16% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 16.53 | 24.86 | 30.41 | 12.54 | 2.47 |
| Price-to-Sales (P/S) Ratio | 1.98 | 3.70 | 3.99 | 3.21 | 0.69 |
| Price-to-Book (P/B) Ratio | 1.36 | 2.32 | 4.15 | 3.95 | 1.75 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.03 | -53.19 | 14.65 | 18.45 | 6.19 |
| Price-to-Operating Cash Flow Ratio | -8.51 | -356.96 | 13.61 | 12.05 | 4.69 |
| Price-to-Earnings Growth (PEG) Ratio | -1.13 | 0.38 | -0.52 | -0.16 | 0.00 |
| Enterprise Value Multiple | 8.60 | 12.57 | 17.68 | 9.14 | 1.92 |
| Enterprise Value | 549.73M | 881.94M | 875.83M | 861.28M | 220.79M |
| EV to EBITDA | 8.60 | 12.57 | 17.68 | 9.14 | 1.92 |
| EV to Sales | 1.45 | 2.61 | 3.57 | 2.83 | 0.58 |
| EV to Free Cash Flow | -4.42 | -37.59 | 13.12 | 16.25 | 5.24 |
| EV to Operating Cash Flow | -6.24 | -252.28 | 12.19 | 10.61 | 3.97 |
| Tangible Book Value Per Share | 0.88 | 0.95 | 0.39 | 0.41 | 0.93 |
| Shareholders’ Equity Per Share | 0.92 | 0.95 | 0.39 | 0.41 | 0.93 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.05 | 0.02 | -0.01 | 0.05 | 0.00 |
| Revenue Per Share | 0.63 | 0.60 | 0.41 | 0.51 | 2.37 |
| Net Income Per Share | 0.08 | 0.09 | 0.05 | 0.13 | 0.66 |
| Tax Burden | 0.95 | 0.98 | 1.01 | 0.95 | 1.00 |
| Interest Burden | 1.13 | 0.97 | 0.95 | 0.99 | 0.99 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.29 | 0.28 | 0.35 | 0.31 | 0.16 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -1.94 | -0.07 | 2.24 | 1.08 | 0.53 |
Currency in THB
